Nostos Genomics partners with genetic testing labs to transform data into genomic insights, enabling fast and clear diagnosis for people with genetic diseases. With over 300 million people affected by rare genetic diseases worldwide, the company aims to reduce the diagnostic odyssey, which currently averages over 5 years. Their CE-certified platform uses a unique combination of machine learning and synthetic biology to automate the laborious and costly interpretation of mutations, significantly accelerating diagnosis and increasing accuracy.

Nostos Genomics seeks to improve the accuracy, speed, and accessibility of genetic testing. They empower patients by providing the right information at the right time, helping them make informed healthcare decisions. Their AI-driven variant interpretation platform, AION, automates variant interpretation in under 2 minutes, delivers white-box explainable AI outputs, and improves diagnostic yield by more than 50% compared to traditional methods.

The company boasts a diverse, interdisciplinary team spanning software development, data science, genetics, and healthcare. They are supported by leading experts and scientific advisors in genomics and clinical genetics. This strong team foundation allows Nostos Genomics to tackle the critical bottleneck in genomic interpretation and innovation in diagnostics.

Nostos Genomics is headquartered in Berlin, Germany, and has between 11-50 employees.

Their platform is GDPR compliant and CE-IVDR certified, ensuring compliance with data protection laws and European regulations for in vitro diagnostics.

LinkedIn: https://www.linkedin.com/company/nostosgenomics
Careers and jobs are hosted on Recruitee at https://nostosgenomics.recruitee.com/